Chemokine receptor CXCR4 and its ligand CXCL12 are suggested to be involved in migration, invasion and metastasis of breast cancer cells. Mutation of the tumor suppressor gene p53 in breast cancer is associated with metastasis and aggressive clinical phenotype. In this report, we demonstrate that wild type but not the dominant-negative mutant (V143A) or cancer-specific mutants (R175H or R280K) of p53 repress CXCR4 expression. Recently described cancer-specific p53 isoform, D133p53, also failed to repress CXCR4 promoter activity. Short-interfering RNA-mediated depletion of p53 increased endogenous CXCR4 expression in MCF-7 breast cancer cells that contain wild-type p53. Basal CXCR4 promoter activity in HCT116 colon carcinoma cells deleted of p53 [HCT116(p53KO)] was 10-fold higher compared to that in parental HCT116 cells with functional wild-type p53. Deletion analysis of CXCR4 promoter identified a seven-base pair p53-repressor element homologous to cyclic AMP/AP-1 response (CRE/AP-1) element. Electrophoretic mobility shift and chromatin immunoprecipitation assays revealed binding of ATF-1 and cJun to the CRE/AP-1 element. The p53 rescue drug PRIMA-1 reduced CXCR4 mRNA and cell surface expression in MDA-MB-231 cells, which express R280K mutant p53. CP-31398, another p53 rescue drug, similarly reduced cell surface levels of CXCR4. PRIMA-1-mediated decrease in CXCR4 expression correlated with reduced invasion of MDA-MB-231 cells through matrigel. These results suggest a mechanism for elevated CXCR4 expression and metastasis of breast cancers with p53 mutations or isoform expression. We propose that p53 rescue drugs either alone or in combination with chemotherapeutic drugs may be effective in reducing CXCR4-mediated metastasis.
Introduction
CXCR4, a seven transmembrane G-coupled receptor protein originally identified as a coreceptor for T cell line tropic strains of human immunodeficiency virus, is expressed on a wide variety of tissue/organ-specific stem cells (Kucia et al., 2005) . It is activated upon binding its ligand CXCL12, also called stromal cell-derived factor (SDF-1a). CXCR4:CXCL12-activated signals cause calcium flux, matrix metalloproteinase 2 (MMP-2) and MMP-9 activation, chemotaxis and chemoinvasion (Kucia et al., 2005) .
CXCR4 is overexpressed in cancer and plays a role in invasion and metastasis (Balkwill, 2004) . Several studies using animal models have suggested a role for CXCR4 in metastasis of breast cancer cells (Muller et al., 2001; Kang et al., 2003; Smith et al., 2004; Liang et al., 2005) . CXCR4 is part of the bone and lung metastasis signatures for breast cancer (reviewed in Gupta et al., 2005) . Recently, we reported CXCR4-mediated repression of major histocompatibility (MHC) class II gene expression, which could lead to evasion of antitumor immunity (Sheridan et al., 2006) . CXCR4 expression is regulated by von HippelLindau tumor suppressor pVHL, vascular endothelial growth factor, hepatocyte growth factor, USF/c-Myc, YY1, nuclear factor-kappa B (NF-kB) and by promoter methylation (Moriuchi et al., 1999; Bachelder et al., 2002; Helbig et al., 2003; Staller et al., 2003; Lee et al., 2005; Matteucci et al., 2005; Mori et al., 2005) . In this study, we examined the possibility that CXCR4 is negatively regulated by the tumor suppressor protein p53. p53 mutation is a late event in breast cancer and is associated with poor response to systemic therapy (Berns et al., 2000) . Moreover, cancer-specific p53 isoforms with dominant-negative activity have been identified (Bourdon et al., 2005) . p53 is a sequencespecific DNA-binding protein that induces expression of several growth arrest and proapoptotic genes (Vousden and Lu, 2002) . It also represses gene expression by binding to p53-repressor elements or through proteinprotein interaction (Fridman and Lowe, 2003) . Here, we show that wild-type p53 but not the cancer-specific mutants or D133p53 isoform represses CXCR4 expression in breast cancer cells. p53-mediated repression requires a cyclic AMP/AP-1 response (CRE/AP-1) like element in the CXCR4 promoter, which binds to cJun and the CRE-building protein (CREB) family transcription factor ATF-1 (activating transcription factor) (Mayr and Montminy, 2001 ). We also show that p53 rescue drug PRIMA-1 at a non-toxic dose reduces CXCR4 expression and invasion of breast cancer cells expressing mutated p53 (Bykov et al., 2002b) .
Results
Transcription factor binding motif search of the CXCR4 promoter revealed the presence of two sequence motifs that are 87% (À2249 to À2239) and 85% (À846 to À837) homologous to the consensus p53 binding site (Caruz et al., 1998) . To test regulation of CXCR4 expression by p53, we adopted three complementary approaches: (1) Analysis of basal CXCR4 expression in parental MCF-7 cells and the same cell line transfected with siRNA against p53. (2) Co-transfection experiments in MCF-7 cells with CXCR4 promoter-reporters and wild-type or mutant p53 expression vectors. Similar studies in HCT116 colon carcinoma cells with wild-type p53 and the same cell line with p53 deletion [HCT116(p53KO)] (Bunz et al., 2002) . (3) Evaluating the ability of p53 rescue drugs to alter CXCR4 expression in MDA-MB-231 cells, which expresses R280K mutant-p53 (Bykov et al., 2002b) .
MCF-7 cells with reduced p53 levels show elevated CXCR4 expression compared to parental cells MCF-7 breast cancer cells contain functional wild-type p53 (Casey et al., 1991) and express low levels of CXCR4. We investigated whether reducing the levels of p53 in these cells by siRNA leads to elevated CXCR4 levels. Northern analysis and flow cytometry analysis showed elevated CXCR4 expression in p53 siRNAtreated cells compared to control luciferase siRNAtreated cells (Figure 1a and b, respectively). Quantitative real-time polymerase chain reaction (RT-PCR) analysis revealed 1.570.15-fold increase in CXCR4 mRNA in p53 siRNA-transfected cells compared to luciferase siRNA-transfected cells (data not shown). In contrast to CXCR4, expression of p21, a p53 target gene, was reduced in p53 siRNA-transfected cells (Figure 1a) . Elevated CXCR4 expression in p53 siRNA transfected cells was not due to the secondary effect of p53 depletion on cell cycle because both luciferase and p53 siRNAtransfected cells showed similar cell-cycle distribution pattern (Figure 1b) . Majority of cells were at G0/G1 phase, because cells had to be maintained in media lacking estrogen to prevent estrogen receptor from repressing CXCR4 expression (Frasor et al., 2003) .
We performed reciprocal experiment in MDA-MB-231 cells. MDA-MB-231 cells that were isolated after implantation into mammary fat pad of nude mice (TMD-231) were used in these studies, because CXCR4 is expressed at much higher levels in these cells compared to parental cells (Helbig et al., 2003) . Wildtype p53 reduced CXCR4 expression in these cells (Figure 1c ).
Wild type but not mutants or isoform of p53 represses CXCR4 promoter activity To determine the ability of mutant p53 to repress CXCR4 and to identify promoter elements involved in p53-mediated repression of CXCR4, we performed cotransfection experiments in MCF-7 breast cancer cells with CXCR4 promoter-reporters and p53 expression vectors. Wild-type p53 but not the dominant-negative mutant (p53V143A) reduced the activity of luciferase reporter controlled by 2.6 kB CXCR4 promoter-enhancer region (Figure 2a) . In TMD-231 cells, wild-type p53 but not p53R280K mutant reduced CXCR4 expression (Figure 2a ).
To determine whether p53-mediated repression of the CXCR4 promoter involves putative p53 response elements, we measured the effect of p53 on the activity of a different CXCR4-promoter-reporter lacking both putative p53 response elements [CXCR4(À827/ þ 7)/ CAT] (Helbig et al., 2003) . CXCR4(À827/ þ 7)/CAT reporter activity was reduced by p53 ( Figure 2b ). These results suggest that p53 represses CXCR4 expression independent of putative p53 response elements. Under identical transfection conditions, p53 increased the activity of p21 promoter-enhancer or consensus p53 response element-driven reporters in both cell types (data not shown).
We next examined the effect of the dominant-negative (p53V143A) and two cancer-specific mutants of p53 with distinct biological activities (p53R175H or p53R280K) on CXCR4 reporter activity (Scian et al., 2004) . Neither the dominant-negative mutant nor cancer-specific mutants repressed CXCR4 reporter activity, suggesting that cancer-specific mutations abrogate the ability of p53 to repress CXCR4 expression ( Figure 2b ).
The D133p53 isoform reduces apoptosis mediated by wild-type p53, suggesting dominant-negative effect on certain p53 functions (Bourdon et al., 2005) . This isoform failed to repress CXCR4 promoter activity in MCF-7 cells (Figure 2b ), although it could increase the levels of endogenous full-length p53 (Figure 2c ). Note that the wild-type and mutants of p53 are expressed at similar levels in transfected cells (Figure 2c) .
We compared the CXCR4 promoter activity in HCT116 and HCT116(p53KO) cells. CXCR4 promoter activity was more than 10-fold higher in HCT116(p53KO) cells compared to HCT116 cells and cotransfected p53 reduced the CXCR4 promoter activity in these cells (Figure 2d ). Taken together, these results suggest the presence of p53-repressible element in the CXCR4 promoter.
CRE/AP-1-like element in the CXCR4 promoter is required for p53-mediated repression To identify the p53-repressor element within the CXCR4 promoter, we used additional deletion mutants of the CXCR4/CAT reporter: CXCR4(À426)/CAT, CXCR4(À209)/CAT and CXCR4(À127)/CAT (Helbig et al., 2003) . p53 repressed the activities of CXCR4(À426)/CAT and CXCR4(À209)/CAT reporters but not the CXCR4(À127)/CAT reporter (Figure 3a) , suggesting the presence of p53-repressor element within À209 to À127 region of the CXCR4 promoter. The fact that CXCR4(À127)/CAT reporter activity was not suppressed by p53 indicates that the observed repression with other CXCR4 promoter reporters is not due to nonspecific effect of p53 overexpression or due to p53-mediated apoptosis of transfected cells.
The À209 to À127 region of the CXCR4 promoter contains sequence elements that bind to SP-1, CRE/AP-1 and Ets-1 family transcription factors (Caruz et al., 1998) (Figure 3a ). p53 has previously been shown to repress gene expression by interacting with or modulating the activity of SP-1, AP-1 and Ets-1 (Bargonetti et al., 1997; Kim et al., 2003; Sun et al., 2004) . We analysed the ability of p53 to repress CXCR4/CAT reporters with mutations in either SP-1 or Ets-binding sites or a mutant lacking CRE/AP-1 element [CXCR4(À199)/CAT]. The activities of both SP-1 and Ets-1 mutant CXCR4 promoter-reporters were repressed by p53, suggesting that neither SP-1 nor Ets-1 is involved in p53-mediated repression of CXCR4 (data not shown). In contrast, p53 failed to repress the activity of the CXCR4(À199)/CAT reporter (Figure 3b) . Thus, the transcription factor(s) that bind(s) to the CRE/AP-1 element is involved in p53-mediated repression of CXCR4. p53-repressor element in the CXCR4 promoter binds ATF-1 and c-Jun We used electrophoretic mobility shift assay (EMSA) to identify transcription factors that bind to the CRE/AP-1 element of the CXCR4 promoter. Experiments were carried out with extracts from cells that were treated with 12-O-tetradecanoylphorbol-13-acetate (TPA), a known inducer of AP-1-DNA binding activity (Shaulian and Karin, 2002) . Two DNA-protein complexes were detected when the CRE/AP-1 element was incubated with nuclear extracts from HCT116 and HCT116(p53KO) cells with or without TPA treatment (Figure 4a) . Also, similar DNA:protein complexes were obtained when extracts from HCT116(p53KO) and same cells transfected with p53 were used in EMSA (data not shown). Similar DNA:protein complexes with nuclear extracts of HCT116, HCT116(p53KO) and HCT116(p53KO) cells transfected with p53 suggests that p53 does not alter protein binding to CRE/AP-1 element. Another complex was detected with nuclear extracts from MCF-7 cells (complex II). Antibody against ATF-1 supershifted complex I. Antibodies against p53, ATF-2, ATF-3, cJun, SP-1 and CREB-1/2 had no effect on DNA:protein complexes. Binding of p53 to CRE/AP-1 element was not observed when nuclear extract from MCF-7 cells overexpressing p53 was used (data not shown). As a control, we measured the binding of p53 from MCF-7 cells to the consensus p53 response element (Supplementary Figure S1) . Sensitive chromatin immunoprecipitation assay (CHIP) also failed to detect binding of p53 to the CXCR4 promoter (data not shown). However, CHIP assay revealed binding of ATF-1 and cJun to the CRE/AP-1 element of the CXCR4 promoter (Figure 4b ).
p53 rescue drugs decrease cell-surface expression of CXCR4 PRIMA-1 and CP-31398 have been effective in in vitro and/ or in vivo studies in restoring certain function to mutated p53 including the R280K mutant p53 present in MDA-MB-231 cells (Foster et al., 1999; Bykov et al., 2002b) .
We investigated by flow cytometry and/or Northern blot analysis whether PRIMA-1 or CP31398 can reduce CXCR4 expression in TMD-231 cells. Cell surface expression of CXCR4 in TMD-231 cells was reduced to 40 and 20% in cells treated with 10 and 20 mM PRIMA-1, respectively (Figure 5a and b) . Mean fluorescence intensity of CXCR4 staining was also reduced in cells treated with PRIMA-1 (data not shown). These results suggest that mutant p53, when rescued by PRIMA-1, can decrease CXCR4 expression. At the concentration of drug used, cells did not undergo apoptosis as determined Trypan blue exclusion assay (data not shown). CP-31398 also reduced cell surface expression of CXCR4 in TMD-231 cells (Figure 5c and  d) . PRIMA-1 reduced CXCR4 mRNA without effecting Figure S2) .
PRIMA-1 reduces invasion of TMD-231 cells through matrigel CXCR4 has been shown to increase invasive capacity of cancer cells (Balkwill, 2004) . We performed matrigel invasion assay to determine whether PRIMA-1 reduces the invasive capacity of TMD-231 cells with or without CXCL12 treatment. Cells were treated with 20 mM PRIMA-1 for 48 h and excess PRIMA-1 was removed by washing. Equal numbers of viable control and PRIMA-1-treated cells were assayed for invasion with or without CXCL12 treatment (Materials and methods in Supplementary file). CXCL12 treatment caused a modest increase in invasive capacity of these cells, which was not statistically significant ( Figure 6 ). Invasion of CXCL12-treated cells was reduced significantly by PRIMA-1 (Figure 6 , Pp0.01). Thus, reduced invasion of PRIMA-1 treated cells correlates with inhibition of CXCR4 expression.
Discussion
We present evidence for p53-mediated repression of CXCR4. Because CXCR4 overexpression and p53 mutations are common in cancers, our study suggests a link between these two major signaling pathways involved in cancer progression (Vousden and Lu, 2002; Balkwill, 2004) . In breast cancer, CXCR4 expression increases progressively with increasing malignant potential and higher expression is associated with lymph node positivity, hormone receptor negativity, Her2 overexpression and poor survival (Cabioglu et al., 2005; Salvucci et al., 2005) . These studies, however, did not compare CXCR4 expression with p53 status. Elevated CXCR4 expression in clinically aggressive cancers could be due to p53 mutation, both of which are associated with poor clinical outcome (Berns et al., 2000) . We have previously shown in a xenograft model that CXCR4-positive cancer cells are clonally selected in primary tumors and at sites of metastasis (Helbig et al., 2003) . It is possible that a subpopulation of cancer cells with impaired p53 activity has elevated CXCR4 expression and these cells are selected for growth at sites of metastasis.
A previous study has shown a relationship between CXCR4:CXCL12 activated signals and p53 activity (Khan et al., 2005) . Binding of CXCL12 to CXCR4 in neuronal cells leads to p53 acetylation and p21 expression suggesting p53 activation. Thus, it is possible that activated p53 then reduces CXCR4 expression to attenuate CXCL12:CXCR4 signaling and this negative regulatory loop is subject to alterations in cancers.
p53 represses the expression of pro-metastatic and anti-apoptotic genes, which may involve direct binding of p53 to promoters, interaction of p53 with transcription factors such as SP-1, AP-1 and Ets-1, or recruitment of histone deacetylase complexes containing mSin3a (Fridman and Lowe, 2003; Kim et al., 2003; Sun et al., 2004) . Repression of CXCR4 by p53 appears to be indirect because we did not observe direct binding of p53 to the CXCR4 promoter region (Figure 4 ) but requires an element that binds to transcription factors ATF-1 and cJun. Although ATF-1 and cJun are generally considered as transcription activators, ATF-1 can also repress transcription (Dong et al., 2002) . ATF/ CREB mediate repression of cyclin A promoter by human T-cell leukemia virus protein Tax (Kibler and Jeang, 2001) . Crosstalk between AP-1 family members and p53 is well documented, which may involve sequestering of the co-activator p300/CBP (Shaulian and Karin, 2002; Sun et al., 2004) . The p53 may similarly sequester p300/CBP away from the CXCR4 promoter and reduces communication between ATF-1/ cJun and the basal transcription machinery.
PRIMA-1 was identified as a p53 rescue drug from the library of low-molecular-weight compounds from the NCI using Saos-2-His273 cells carrying tetracyclineregulated mutant p53 (Bykov et al., 2002b) . PRIMA-1 is the only compound among 45 tested anticancer agents that selectively induced apoptosis of cell lines with p53 mutation (Bykov et al., 2002a; Li et al., 2005) . In our study, PRIMA-1 reduced CXCR4 expression and invasion of breast cancer cells with mutated p53. These results have important implications because p53 mutations are observed in advanced breast cancers that do not respond to therapy (Berns et al., 2000) . Therefore, a combination of PRIMA-1 and chemotherapeutic drugs may prove to be effective therapy for metastatic breast cancers.
Materials and methods

Plasmid constructs and reagents
The human CXCR4 promoter (À897 to þ 7) and deletion mutants were generated by PCR and are described previously (Helbig et al., 2003) . Details of additional constructs can be found in Supplementary information.
Cancer cell lines, transient transfection assays, CAT assays and luciferase assays
The human breast cancer cell lines MCF-7 and MDA-MB-231 were from American Type Tissue Culture Collection. TMD-231, a tumor-derived variant of MDA-MB-231 cells, has been described previously (Helbig et al., 2003) . Details of growth and transient transfection assay conditions of these cell lines and HCT116 cells are in Supplementary information. siRNA transfection siRNA against p53 and luciferase was purchased from Dharmacon RNA Technology (Lafayette, CO, USA). MCF-7 cells growing in phenol-red free MEM supplemented with 5% charcoal-dextran treated-serum were transfected with 5 nM siRNA using TransIT-TKO transfection reagent (Mirus, Madison, WI, USA). siRNA-transfected cells were analysed 72 h after transfection.
Northern analysis RNA was isolated using the Qiagen RNAeasy kit (Qiagen, Valencia, CA, USA) according to the manufacturer's instructions (see in Supplementary information for additional details).
EMSA
Nuclear extracts of HCT116, HCT116(p53KO) with or without TPA treatment (125 nM for 3 h), MCF-7 cells and MDA-MB-231 cells with or without PRIMA-1 treatment (20 mM for 24 h) were subjected to EMSA with CXCR4-CRE/AP-1, p53 and SP-1 probes as described previously (Helbig et al., 2003) . Details of probes are provided in Supplementary information.
Cell surface expression of CXCR4
Cell surface expression of CXCR4 was measured by flow cytometry as described previously (Helbig et al., 2003) with additional details in Supplementary information.
Invasion assay
Matrigel invasion assays were performed using Cell Invasion Assay kit from Chemicon International (Temecula, CA, USA) as per the manufacturer's protocol. Additional details are in Supplementary information.
Western blot analysis
Details of Western analysis are provided in Supplementary information.
CHIP assay
CHIP assay was performed using CHIP assay kit (Upstate Biotechnology, Lake Placid, NY, USA) as per instructions of the manufacturers. Supplementary Information provides details of the CHIP assay.
